QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
NASDAQ:CDXS

Codexis - CDXS Stock Forecast, Price & News

$3.94
-0.16 (-3.90%)
(As of 03/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.91
$4.19
50-Day Range
$3.81
$6.76
52-Week Range
$3.79
$22.22
Volume
512,368 shs
Average Volume
634,149 shs
Market Capitalization
$259.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.83

Codexis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
378.0% Upside
$18.83 Price Target
Short Interest
Bearish
7.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.67
Upright™ Environmental Score
News Sentiment
0.95mentions of Codexis in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$716,599 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.89) to ($0.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

373rd out of 1,009 stocks

Industrial Organic Chemicals Industry

11th out of 20 stocks


CDXS stock logo

About Codexis (NASDAQ:CDXS) Stock

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Stock News Headlines

StockNews.com Begins Coverage on Codexis (NASDAQ:CDXS)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Q4 2022 Codexis Inc Earnings Call
Codexis Announces New Employment Inducement Grants
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
15 Worst Stock Picks of Cathie Wood in 2022
CDXS.P - | Stock Price & Latest News | Reuters
Codexis Third Quarter 2022 Earnings: Beats Expectations
When Should You Buy Codexis, Inc. (NASDAQ:CDXS)?
See More Headlines
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Company Calendar

Last Earnings
2/23/2023
Today
3/30/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CDXS
CUSIP
19200510
Employees
261
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.83
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+380.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-33,590,000.00
Pretax Margin
-24.04%

Debt

Sales & Book Value

Annual Sales
$138.59 million
Book Value
$2.20 per share

Miscellaneous

Free Float
61,331,000
Market Cap
$258.51 million
Optionable
Optionable
Beta
1.64

Key Executives

  • Stephen George Dilly
    President, CEO & Independent Director
  • Karl A. Schoene
    Senior Vice President-Development & Operations
  • Kevin Norrett
    Chief Operating Officer
  • Sriram Ryali
    Chief Financial & Accounting Officer
  • Stefan Lutz
    Senior Vice President-Research













CDXS Stock - Frequently Asked Questions

Should I buy or sell Codexis stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CDXS shares.
View CDXS analyst ratings
or view top-rated stocks.

What is Codexis' stock price forecast for 2023?

3 analysts have issued 12 month target prices for Codexis' stock. Their CDXS share price forecasts range from $9.00 to $23.00. On average, they anticipate the company's stock price to reach $18.83 in the next twelve months. This suggests a possible upside of 376.8% from the stock's current price.
View analysts price targets for CDXS
or view top-rated stocks among Wall Street analysts.

How have CDXS shares performed in 2023?

Codexis' stock was trading at $4.66 at the beginning of the year. Since then, CDXS stock has decreased by 15.2% and is now trading at $3.95.
View the best growth stocks for 2023 here
.

When is Codexis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our CDXS earnings forecast
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) released its earnings results on Thursday, February, 23rd. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.04. The biotechnology company earned $30.40 million during the quarter, compared to analyst estimates of $28.92 million. Codexis had a negative net margin of 24.24% and a negative trailing twelve-month return on equity of 21.78%. The business's quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.16) EPS.

What guidance has Codexis issued on next quarter's earnings?

Codexis updated its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $63.00 million-$68.00 million, compared to the consensus revenue estimate of $91.98 million.

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (9.42%), Nantahala Capital Management LLC (6.83%), ARK Investment Management LLC (6.00%), Telemark Asset Management LLC (3.96%), Geode Capital Management LLC (1.81%) and Sumitomo Mitsui Trust Holdings Inc. (1.66%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Kevin Norrett, Patrick Y Yang, Stephen George Dilly and Thomas R Baruch.
View institutional ownership trends
.

How do I buy shares of Codexis?

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $3.95.

How much money does Codexis make?

Codexis (NASDAQ:CDXS) has a market capitalization of $260.49 million and generates $138.59 million in revenue each year. The biotechnology company earns $-33,590,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does Codexis have?

The company employs 261 workers across the globe.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102.

This page (NASDAQ:CDXS) was last updated on 3/30/2023 by MarketBeat.com Staff